Identification of Susceptibility to Malignant Hyperpyrexia
- 4 May 1974
- Vol. 2 (5913) , 245-247
- https://doi.org/10.1136/bmj.2.5913.245
Abstract
While the serum level of creatine phosphokinase is useful as a screening test for malignant hyperpyrexia it does not provide certain identification of susceptible individuals. A much more accurate prediction may be made by pharmacological testing in vitro of muscle biopsy specimens. Individuals susceptible to malignant hyperpyrexia have muscle with heightened sensitivity to halothane, caffeine, succinylcholine, potassium chloride, and temperature change. Use of this test allows separation of susceptible individuals from those not at risk in families of patients who have experienced malignant hyperpyrexia.Keywords
This publication has 11 references indexed in Scilit:
- Malignant hyperthermia: an investigation of five patientsCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 1973
- Central-core disease and malignant hyperpyrexia.BMJ, 1973
- Procaine in Malignant HyperpyrexiaBMJ, 1972
- Screening for Malignant HyperpyrexiaBMJ, 1972
- A REVIEW OF THE VALUE OF CREATINE PHOSPHOKINASE ESTIMATIONS IN CLINICAL MEDICINEThe Medical Journal of Australia, 1972
- INHERITANCE OF MALIGNANT HYPERPYREXIAThe Lancet, 1972
- Halothane-induced muscle contracture as a cause of hyperpyrexia.1971
- METABOLIC ERROR OF MUSCLE METABOLISM AFTER RECOVERY FROM MALIGNANT HYPERTHERMIAThe Lancet, 1970
- MYOPATHY AND MALIGNANT HYPERPYREXIAThe Lancet, 1970
- Malignant Hyperpyrexia during Anaesthesia: Possible Association with Subclinical MyopathyBMJ, 1970